NCT00972218View on ClinicalTrials.gov

Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
SpondyloarthritisCrohn's Disease
Interventions
BIOLOGICAL

Adalimumab

Adalimumab subcutaneous injections 40 mg dose every other week for 24 weeks

Trial Locations (1)

T6G2S2

University of Alberta, Edmonton

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

University of Alberta

OTHER